Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection.

Gibb DM, Duong T, Leclezio VA, Walker AS, Verweel G, Dunn DT; Collaborative HIV Paediatric Study Steering Committee.

Pediatr Infect Dis J. 2004 May;23(5):446-50.

PMID:
15131469
2.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
3.

Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.

Ananworanich J, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, Mahanontharit A, Ubolyam S, Cooper D, Phanuphak P, Ruxrungtham K.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):523-9.

PMID:
16044002
4.

Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study.

Walker AS, Doerholt K, Sharland M, Gibb DM; Collaborative HIV Paediatric Study (CHIPS) Steering Committee.

AIDS. 2004 Sep 24;18(14):1915-24.

PMID:
15353977
5.

Discontinuation of antiretroviral therapy in patients with chronic HIV infection: clinical, virologic, and immunologic consequences.

Mata RC, Viciana P, de Alarcón A, López-Cortés LF, Gómez-Vera J, Trastoy M, Cisneros JM.

AIDS Patient Care STDS. 2005 Sep;19(9):550-62.

PMID:
16164382
6.

[Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment].

Pavie J, Porcher R, Fournier S, André F, Tournoux C, Palmer P, Rabian C, Jean-Michel M.

Presse Med. 2005 Jun 4;34(10 Suppl):1S8-13. French.

PMID:
16025661
7.

Response to planned treatment interruptions in HIV infection varies across childhood.

Paediatric European Network for Treatment of AIDS.

AIDS. 2010 Jan 16;24(2):231-41. doi: 10.1097/QAD.0b013e328333d343.

PMID:
20010073
8.

A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.

Fagard C, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L, Plana M, Phillips R, Hirschel B; Swiss HIV Cohort Study.

Arch Intern Med. 2003 May 26;163(10):1220-6.

PMID:
12767960
9.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.

PMID:
18670217
10.

Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care.

Judd A, Doerholt K, Tookey PA, Sharland M, Riordan A, Menson E, Novelli V, Lyall EG, Masters J, Tudor-Williams G, Duong T, Gibb DM; Collaborative HIV Paediatric Study (CHIPS); National Study of HIV in Pregnancy and Childhood (NSHPC).

Clin Infect Dis. 2007 Oct 1;45(7):918-24. Epub 2007 Aug 27.

PMID:
17806062
11.

Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.

Palacios GC, Sanchez LM, Briones E, Ramirez TJ, Castillo H, Rivera LG, Vazquez CA, Rodriguez-Padilla C, Holodniy M.

Int J Infect Dis. 2010 Jan;14(1):e34-40. doi: 10.1016/j.ijid.2009.03.003. Epub 2009 May 20.

12.

Response to highly active antiretroviral therapy according to duration of HIV infection.

Pezzotti P, Pappagallo M, Phillips AN, Boros S, Valdarchi C, Sinicco A, Zaccarelli M, Rezza G; Italian Seroconversion Study.

J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):473-9.

PMID:
11391168
14.

Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.

Resino S, Resino R, Micheloud D, Gurbindo Gutiérrez D, Léon JA, Ramos JT, Ciria L, de José I, Mellado J, Muñoz-Fernández A; Spanish Group of Paediatric HIV Infection.

Clin Infect Dis. 2006 Mar 15;42(6):862-9. Epub 2006 Feb 9.

PMID:
16477566
15.
16.

Retrospective analysis of suspending HAART in selected patients with controlled HIV replication.

Jacobs B, Neil N, Aboulafia DM.

AIDS Patient Care STDS. 2005 Jul;19(7):429-38.

PMID:
16053400
17.

Structured intermittent interruption of chronic HIV infection treatment with highly active antiretroviral therapy: effects on leptin and TNF-alpha.

Arjona MM, Pérez-Cano R, Garcia-Juárez R, Martín-Aspas A, del Alamo CF, Girón-González JA.

AIDS Res Hum Retroviruses. 2006 Apr;22(4):307-14.

18.

Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects.

Moltó J, Ruiz L, Romeu J, Martínez-Picado J, Negredo E, Tural C, Sirera G, Clotet B.

AIDS Res Hum Retroviruses. 2004 Dec;20(12):1283-8.

PMID:
15650419
19.

Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.

Pai NP, Lawrence J, Reingold AL, Tulsky JP.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD006148. Review.

PMID:
16856117
20.

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.

Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M; Swiss HIV Cohort Study Group.

Arch Intern Med. 2003 Oct 13;163(18):2187-95.

PMID:
14557216

Supplemental Content

Support Center